The Phase d Clinical Trial of Hydronidone Capsules
Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-05
Target enrollment:
Participant gender:
Summary
Based on the Phase I (Ia, Ib, Ic) clinical pharmacokinetic study of Hydronidone Capsules, a clinical pharmacokinetic trial of Hydronidone Capsules (specification: 30 mg/capsule) was conducted, including single-dose administration, multiple-dose administration, and a food-effect study. The aim was to investigate the safety, tolerability, and pharmacokinetic characteristics of higher doses of Hydronidone Capsules (specification: 30 mg/capsule) in healthy subjects, in preparation for future expansion of indications.
Phase:
PHASE1
Details
Lead Sponsor:
Beijing Continent Pharmaceutical Co, Ltd.
Collaborator:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology